Fortrea Appoints Agnieszka Gallagher as General Counsel - Fortrea Holdings ( NASDAQ:FTRE )
DURHAM, N.C., Nov. 17, 2025 ( GLOBE NEWSWIRE ) -- Fortrea ( NASDAQ:FTRE ) ( the "Company" ) , a leading global contract research organization ( CRO ) , today announced the appointment of Agnieszka ( Aggie ) M. Gallagher as general counsel.
Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker - Novo Nordisk ( NYSE:NVO )
In a presentation at the American Heart Association's ( AHA's ) 2025 Scientific Sessions, researchers on Tuesday shared data from Novo Nordisk A/S' ( NYSE:NVO ) Coramitug Phase 2 trial for transthyretin amyloidosis with cardiomyopathy ( ATTR-CM ) .
Got $5,000? 3 Top Growth Stocks to Buy That Could Double Your Money
No investment is a slam dunk to double your money. But these great stocks appear to have what it takes.
Here's How Much $1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth Today - Alnylam Pharmaceuticals ( NASDAQ:ALNY )
Alnylam Pharmaceuticals ( NASDAQ:ALNY ) has outperformed the market over the past 20 years by 11.66% on an annualized basis producing an average annual return of 20.5%. Currently, Alnylam Pharmaceuticals has a market capitalization of $58.49 billion.
What Does the Market Think About Alnylam Pharmaceuticals Inc? - Alnylam Pharmaceuticals ( NASDAQ:ALNY )
Alnylam Pharmaceuticals Inc's ( NYSE:ALNY ) short interest as a percent of float has risen 13.65% since its last report. According to exchange reported data, there are now 3.99 million shares sold short, which is 4.08% of all regular shares that are available for trading.
New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline
Basel, November 4, 2025 - Novartis will present new data from 33 abstracts across its Cardiovascular, Renal, and Metabolic ( CRM ) disease portfolio at the upcoming American Society of Nephrology ( ASN ) Kidney Week 2025 in Houston, Texas and American Heart Association's ( AHA ) Scientific ...
's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet - Alnylam Pharmaceuticals ( NASDAQ:ALNY ) , American Airlines Group ( NASDAQ:AAL )
Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and deserve attention. Investors are constantly on the hunt for undervalued, under-followed and emerging stocks.
ALNY Q3 Earnings and Revenues Top Estimates on Higher Amvuttra Sales
Alnylam's Q3 earnings and revenues surge past forecasts, powered by booming Amvuttra sales and a key milestone payment from Roche.
Why Is Alnylam Pharmaceuticals Stock Trading Lower Thursday? - Alnylam Pharmaceuticals ( NASDAQ:ALNY )
Alnylam Pharmaceuticals Inc. ( NASDAQ:ALNY ) stock is trading lower after the company reported third-quarter earnings. Alnylam also said that it received a subpoena from the U.S.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Alnylam Pharmaceuticals ( ALNY ) Q3 Earnings and Revenues Top Estimates
Alnylam (ALNY) delivered earnings and revenue surprises of +73.65% and +22.25%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zoetis Gears Up to Report Q3 Earnings: Here's What to Expect
ZTS is poised for another earnings beat as rising demand for companion animal products like Simparica Trio and Apoquel drives expected Q3 revenue growth.
Amgen's Q3 Earnings in the Cards: Here's What to Expect
Amgen's Q3 results are on deck, with growth from newer drugs offset by biosimilar competition and pricing pressures.
Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
Strong Trikafta/Kaftrio demand, along with contributions from Alyftrek, Casgevy and Journavx, may have helped VRTX outperform in the third quarter.
Exploring Analyst Estimates for Alnylam ( ALNY ) Q3 Earnings, Beyond Revenue and EPS
Evaluate the expected performance of Alnylam (ALNY) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Balancing Innovation and Income: A2 Fund Shares 2026 Market Outlook Following 75% YTD Fund Growth
WILMINGTON, Del., Oct. 28, 2025 /PRNewswire/ -- A2 Management, the investment adviser behind the A2 Growth Opportunities Fund, today released its 2026 market outlook, highlighting strategies that balance innovation-driven growth with consistent monthly income.
Is First Trust NYSE Arca Biotechnology ETF ( FBT ) a Strong ETF Right Now?
Smart Beta ETF report for ...
ANI Pharmaceuticals to Report Q3 Earnings: Is a Beat in the Cards?
ANIP's rising Cortrophin Gel sales and new rare disease products, along with generic and other segments, could power another earnings beat this quarter.
Krystal Biotech, Inc. ( KRYS ) Reports Next Week: Wall Street Expects Earnings Growth
Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline?
Regeneron's Q3 earnings on Oct. 28 will likely spotlight Dupixent profits and strong Eylea HD uptake amid lingering Eylea competition.
Viking Therapeutics Posts Wider-Than-Expected Loss in Q3, Sales Nil
VKTX posts a wider Q3 loss and no sales, as R&D costs surge and obesity drug studies drive spending higher.
IQVIA Gears Up to Report Q3 Earnings: What's in the Cards?
IQV readies its Q3 report, with revenues and EPS expected to rise on biopharma strength and cost control despite muted beat odds.
Alnylam Pharmaceuticals ( ALNY ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NVO Stock Falls Amid Governance Shift as Foundation Seeks New Board
Novo Nordisk stock slides as the Novo Nordisk Foundation pushes a sweeping board overhaul, signaling a new era in governance and strategic direction.
Peering Into Alnylam Pharmaceuticals Inc's Recent Short Interest - Alnylam Pharmaceuticals ( NASDAQ:ALNY )
Alnylam Pharmaceuticals Inc's ( NYSE:ALNY ) short interest as a percent of float has fallen 5.53% since its last report. According to exchange reported data, there are now 3.51 million shares sold short, which is 3.59% of all regular shares that are available for trading.
Roche's Gazyva Secures FDA Nod for Label Expansion in Lupus Nephritis
RHHBY secures FDA approval to expand Gazyva's label for treating lupus nephritis, offering patients a faster and more convenient treatment option.
NVO's Rybelsus Gets FDA Nod to Reduce Heart Risk in Diabetes Patients
Novo Nordisk secures FDA approval for Rybelsus as the first oral GLP-1 therapy proven to cut major heart risks in adults with type II diabetes.
Why Alnylam ( ALNY ) Might be Well Poised for a Surge
Alnylam Pharmaceuticals (ALNY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Viatris Acquires Aculys Pharma to Expand Neurology Portfolio in Japan
VTRS acquires Aculys Pharma to boost its CNS portfolio in Japan, gaining rights to pitolisant and Spydia for narcolepsy and seizure management, respectively.
Are You Looking for a Top Momentum Pick? Why Alnylam Pharmaceuticals ( ALNY ) is a Great Choice
Does Alnylam Pharmaceuticals (ALNY) have what it takes to be a top stock pick for momentum investors? Let's find out.
RCKT Stock Up as FDA Accepts Resubmitted BLA for Gene Therapy
Rocket Pharmaceuticals surges as the FDA accepts its resubmitted BLA for Kresladi, a gene therapy targeting the rare LAD-I disorder.
Is the Options Market Predicting a Spike in Alnylam Pharmaceuticals Stock?
Investors need to pay close attention to ALNY stock based on the movements in the options market lately.
Astria Therapeutics Stock Rallies 37% on $700M Buyout Offer From BCRX
ATXS stock jumps 37% after agreeing to a $700 million cash-and-stock buyout by BioCryst, boosting the latter's HAE treatment pipeline.
$1000 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth This Much Today - Alnylam Pharmaceuticals ( NASDAQ:ALNY )
Alnylam Pharmaceuticals ( NASDAQ:ALNY ) has outperformed the market over the past 10 years by 7.28% on an annualized basis producing an average annual return of 19.82%. Currently, Alnylam Pharmaceuticals has a market capitalization of $59.73 billion.
TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals
Tvardi Therapeutics' shares crater after its phase II idiopathic pulmonary fibrosis study shows no meaningful benefit from TTI-101 therapy compared to placebo.
Here's Why Alnylam Pharmaceuticals ( ALNY ) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is Alnylam Pharmaceuticals ( ALNY ) Outperforming Other Medical Stocks This Year?
Here is how Alnylam Pharmaceuticals (ALNY) and ALX Oncology Holdings Inc. (ALXO) have performed compared to their sector so far this year.
's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet - Alnylam Pharmaceuticals ( NASDAQ:ALNY ) , Agnico Eagle Mines ( NYSE:AEM )
Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and deserve attention. Investors are constantly on the hunt for undervalued, under-followed and emerging stocks.
Should Invesco NASDAQ Next Gen 100 ETF ( QQQJ ) Be on Your Investing Radar?
Style Box ETF report for ...
Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?
ALNY's portfolio of rare disease and cardiovascular drugs is boosting revenues and reducing reliance on Amvuttra.
Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President - Ultragenyx Pharmaceutical ( NASDAQ:RARE )
NOVATO, Calif., Sept. 30, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. ( NASDAQ:RARE ) today announced the appointment of Eric Olson as chief business officer ( CBO ) and executive vice president effective September 22, 2025, following the planned retirement of Thomas Kassberg.
Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President
NOVATO, Calif., Sept. 30, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. ( NASDAQ: RARE ) today announced the appointment of Eric Olson as chief business officer ( CBO ) and executive vice president effective September 22, 2025, following the planned retirement of Thomas Kassberg.
$1000 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth This Much Today - Alnylam Pharmaceuticals ( NASDAQ:ALNY )
Alnylam Pharmaceuticals ( NASDAQ: ALNY ) has outperformed the market over the past 5 years by 10.45% on an annualized basis producing an average annual return of 25.22%. Currently, Alnylam Pharmaceuticals has a market capitalization of $57.78 billion.
What's Going On With Intellia Therapeutics Stock Thursday - Intellia Therapeutics ( NASDAQ:NTLA )
Intellia Therapeutics Inc. ( NASDAQ: NTLA ) on Thursday released longer-term follow-up data from the ongoing Phase 1 study of investigational nexiguran ziclumeran ( nex-z ) for the treatment of hereditary ATTR amyloidosis with polyneuropathy ( ATTRv-PN ) .
Why Alnylam Pharmaceuticals ( ALNY ) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Is SPDR S&P Biotech ETF ( XBI ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Alnylam ( ALNY ) Surges 6.0%: Is This an Indication of Further Gains?
Alnylam (ALNY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Here's How Much $1000 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth Today - Alnylam Pharmaceuticals ( NASDAQ:ALNY )
Alnylam Pharmaceuticals ALNY has outperformed the market over the past 10 years by 3.04% on an annualized basis producing an average annual return of 15.62%. Currently, Alnylam Pharmaceuticals has a market capitalization of $58.59 billion.
Can ALNY's Key Partnerships With Pharma Giants Drive Long-Term Growth?
Alnylam's strong drug sales and advancing partnerships with Regeneron and Roche highlight key growth drivers in the quarters ahead.
Are Options Traders Betting on a Big Move in Alnylam Pharmaceuticals Stock?
Investors need to pay close attention to Alnylam Pharmaceuticals stock based on the movements in the options market lately.
